Celgene's Revlimid looks approvable for early use in blood cancer
This article was originally published in Scrip
Executive Summary
Celgene’s Revlimid potentially can be the new standard of care for treating early stage cases of the blood cancer multiple myeloma, a researcher told doctors at a major medical meeting.